Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Small-Cell Lung Cancer (SCLC) Market Spotlight Report 2017 - Research and Markets

Research and Markets
Posted on: 08 Nov 17

The "Market Spotlight: Small-Cell Lung Cancer (SCLC)" report has been added to Research and Markets' offering.

This Market Spotlight report covers the small cell lung cancer market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

  • The author estimates that in 2016, there were 288,800 incident cases of small cell lung cancer (SCLC) worldwide, and forecasts that number to increase to 316,300 incident cases by 2025.
  • Northern America is estimated to have the highest disease incidence (10.26 per 100,000 people), while Africa has the lowest incidence (0.42 per 100,000 people).
  • Owing to the rapid disease progression and the development of drug resistance during the disease course, treatment of SCLC remains very challenging.
  • Therapies in mid and late-stage development for SCLC focus on a variety of targets. The majority of the drugs in mid-to-latestage development for SCLC are administered via the intravenous route, with the remainder being oral, intramuscular, and subcutaneous.
  • Novartis's Hycamtin (topotecan) and Aeterna Zentaris's lobaplatin, which target topoisomerase I and DNA, respectively, are the only marketed drugs for SCLC. Hycamtin is widely approved, while lobaplatin is only approved in China.
  • High impact upcoming events for drugs in the SCLC space include topline Phase II and IIb, and Phase III trial results. Licensing and asset acquisition activity involving SCLC drugs has been weak during 201217, with only nine deals over this time period. The $356m license agreement between CytRx and NantCell for the exclusive rights to develop and market aldoxorubicin, was the largest deal during 201217.
  • Opdivo's peak sales potential surpasses its competitors, although the majority of forecast sales are for indications other than small cell lung cancer.
  • The clinical trials distribution across Phase I-IV indicates that the majority of the drugs are in early and mid phases of development, with 88% of trials in Phase I-II, and only 12% in Phase III-IV.
  • The US has a substantial lead in the number of small cell lung cancer clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.
  • Pfizer has carried out the most Phase III trials in small cell lung cancer, with 8 trials, followed by GlaxoSmithKline and BristolMyers Squibb which have each sponsored 6 Phase III trials.

Key Topics Covered:

1 Key Takeaways

2 Disease Background

3 Treatment

4 Epidemiology

5 Pipeline Drugs

6 Marketed Drugs

7 Key Upcoming Events

8 Licensing And Asset Acquisition Deals

9 Parent Patents

10 Revenue Opportunity

11 Clinical Trial Landscape

12 Bibliography

For more information about this report visit

View source version on

Business Wire

Last updated on: 08/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.